BACKGROUND Autoimmune gastritis(AIG)is a progressive,chronic,immune-mediated inflammatory disease characterized by the destruction of gastric parietal cells leading to hypo/anacidity and loss of intrinsic factor.Gastr...BACKGROUND Autoimmune gastritis(AIG)is a progressive,chronic,immune-mediated inflammatory disease characterized by the destruction of gastric parietal cells leading to hypo/anacidity and loss of intrinsic factor.Gastrointestinal symptoms such as dyspepsia and early satiety are very common,being second in terms of frequency only to anemia,which is the most typical feature of AIG.AIM To address both well-established and more innovative information and knowledge about this challenging disorder.METHODS An extensive bibliographical search was performed in PubMed to identify guidelines and primary literature(retrospective and prospective studies,systematic reviews,case series)published in the last 10 years.RESULTS A total of 125 records were reviewed and 80 were defined as fulfilling the criteria.CONCLUSION AIG can cause a range of clinical manifestations,including dyspepsia.The pathophysiology of dyspepsia in AIG is complex and involves changes in acid secretion,gastric motility,hormone signaling,and gut microbiota,among other factors.Managing dyspeptic symptoms of AIG is challenging and there are no specific therapies targeting dyspepsia in AIG.While proton pump inhibitors are commonly used to treat dyspepsia and gastroesophageal reflux disease,they may not be appropriate for AIG.Prokinetic agents,antidepressant drugs,and non-pharmacological treatments may be of help,even if not adequately evidence-based supported.A multidisciplinary approach for the management of dyspepsia in AIG is recommended,and further research is needed to develop and validate more effective therapies for dyspepsia.展开更多
Purpose:To explore the effect of the clinical treatment of chronic atrophic gastritis Methods:70 patients with chronic atrophic gastritis treated in our hospital from October 2017 to November 2018 were selected and ra...Purpose:To explore the effect of the clinical treatment of chronic atrophic gastritis Methods:70 patients with chronic atrophic gastritis treated in our hospital from October 2017 to November 2018 were selected and randomly divided into an observation group and a control group with 35 patients in each group.The control group received standard triad treatment with gastroprokinetic drug orally.On the basis of the control group,patients in the observation group received Xianlu Pazhu Wan.The treatment efficiency,eradication rate of helicobacter pylori(H.pylori),incidence of adverse effects and length of stay were compared between the two groups.Results:Compared with the control group,patients in the observation group had higher treatment efficiency,higher H.pylori eradication rate,lower incidence of adverse effects,and shorter length of stay with statistical significance(P<0.05).Conclusion:In the clinical treatment of patients with chronic atrophic gastritis,adding Xianlu Pazhu Wan into the basic medication plan can have better treatment efficiency,reduce the incidence of adverse effects,and shorten the length of stay.Therefore,Xianlu Pazhu Wan should be promoted in the practice.展开更多
Objective To investigate the clinical and pathological outcome of gastric mucosa lesions in chronic atrophic gastritis treated with Helicobacter pylori(H.pylori)eradication combined with folic acid(three months treatm...Objective To investigate the clinical and pathological outcome of gastric mucosa lesions in chronic atrophic gastritis treated with Helicobacter pylori(H.pylori)eradication combined with folic acid(three months treatments).Methods From December 2009 to December2010,outpatients with chronic atrophic gastritis were selected and divided into H.pylori positive group and H.展开更多
文摘BACKGROUND Autoimmune gastritis(AIG)is a progressive,chronic,immune-mediated inflammatory disease characterized by the destruction of gastric parietal cells leading to hypo/anacidity and loss of intrinsic factor.Gastrointestinal symptoms such as dyspepsia and early satiety are very common,being second in terms of frequency only to anemia,which is the most typical feature of AIG.AIM To address both well-established and more innovative information and knowledge about this challenging disorder.METHODS An extensive bibliographical search was performed in PubMed to identify guidelines and primary literature(retrospective and prospective studies,systematic reviews,case series)published in the last 10 years.RESULTS A total of 125 records were reviewed and 80 were defined as fulfilling the criteria.CONCLUSION AIG can cause a range of clinical manifestations,including dyspepsia.The pathophysiology of dyspepsia in AIG is complex and involves changes in acid secretion,gastric motility,hormone signaling,and gut microbiota,among other factors.Managing dyspeptic symptoms of AIG is challenging and there are no specific therapies targeting dyspepsia in AIG.While proton pump inhibitors are commonly used to treat dyspepsia and gastroesophageal reflux disease,they may not be appropriate for AIG.Prokinetic agents,antidepressant drugs,and non-pharmacological treatments may be of help,even if not adequately evidence-based supported.A multidisciplinary approach for the management of dyspepsia in AIG is recommended,and further research is needed to develop and validate more effective therapies for dyspepsia.
文摘Purpose:To explore the effect of the clinical treatment of chronic atrophic gastritis Methods:70 patients with chronic atrophic gastritis treated in our hospital from October 2017 to November 2018 were selected and randomly divided into an observation group and a control group with 35 patients in each group.The control group received standard triad treatment with gastroprokinetic drug orally.On the basis of the control group,patients in the observation group received Xianlu Pazhu Wan.The treatment efficiency,eradication rate of helicobacter pylori(H.pylori),incidence of adverse effects and length of stay were compared between the two groups.Results:Compared with the control group,patients in the observation group had higher treatment efficiency,higher H.pylori eradication rate,lower incidence of adverse effects,and shorter length of stay with statistical significance(P<0.05).Conclusion:In the clinical treatment of patients with chronic atrophic gastritis,adding Xianlu Pazhu Wan into the basic medication plan can have better treatment efficiency,reduce the incidence of adverse effects,and shorten the length of stay.Therefore,Xianlu Pazhu Wan should be promoted in the practice.
文摘Objective To investigate the clinical and pathological outcome of gastric mucosa lesions in chronic atrophic gastritis treated with Helicobacter pylori(H.pylori)eradication combined with folic acid(three months treatments).Methods From December 2009 to December2010,outpatients with chronic atrophic gastritis were selected and divided into H.pylori positive group and H.
